Skip to Main Content

Good morning. Elizabeth Cooney here, filling in for Ed Silverman. Heads-up: Our STAT colleague Helen Branswell will answer questions about Ebola, vaccines, and a new epidemic in a free live chat at 1 p.m. ET today. Sign up here.

Markups on commonly prescribed generic drugs are growing, with huge markups on some well-known medicines, a Bloomberg analysis found. For the 90 drugs analyzed, including more than 500 dosages and formulations, pharmacy benefit managers and pharmacies siphoned off $1.3 billion of the $4.2 billion Medicaid insurers spent on the drugs in 2017. The biggest markups tended to come on newer generic drugs. In 2017, markups in some states increased the price paid by state Medicaid plans for generic versions of the Novartis (NVS) leukemia pill Gleevec by as much as $3,000 per prescription.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!